OBJECTIVE: To observe the clinical efficacy of cetuximab plus chemotherapy in the treatment of metastatic @entity14 . METHODS: Clinicopathological data of 128 @entity1 with metastatic @entity14 admitted in the Department of Oncology, Chinese PLA General Hospital from 2008 to June 2012 were analyzed retrospectively. Among them, 91 @entity1 received cetuximab as the first-line therapy and 37 in the second-line or more-line therapy. The chemotherapy regimens included @entity901 -based therapy (FOLFOX/XELOX), @entity2600 -based therapy (FOLFIRI/XELIRI) and @entity1487 -based therapy (Xeloda). The efficacy was evaluated according to RECIST 1.0 criteria. The remission rate, control rate and time to disease progression were compared among @entity1 receiving cetuximab combined with different chemotherapy regimens in different periods. RESULTS: The disease control rate of cetuximab applied in the first-line treatment was higher than that of the second-line or more-line [85.9%(61/71) vs. 59.3%(16/27), P=0.004]. The disease control rate of the group treated with cetuximab plus @entity901 -based chemotherapy was much higher compared to the other two groups [91.1%(41/45) vs. 68.1%(32/47), 4/6, P=0.021]. But there were no significant differences among three regimens in the terms of overall response rate(all P>0.05). The median time to progression of groups with cetuximab plus @entity2600 , @entity901 or @entity416 was 7.8 months, 8.5 months and 5.2 months respectively. The median time to progression of cetuximab combined with chemotherapy in the first-line treatment and the second-line or more-line was 8.2 and 7.7 months respectively. However, the differences were not statistically significant(P>0.05). CONCLUSIONS: Cetuximab in combination with @entity901 -based chemotherapy is recommended as the first-line application in the treatment of metastatic @entity14 @entity1 , because it is helpful to improve the rate of disease control.

[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinoma', 'colorectal cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal carcinoma']
